Search
R673
go.drugbank.com/drugs/DB05466ExperimentalThe phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but SP levels have been commonly linked to the functioning
Vevorisertib
go.drugbank.com/drugs/DB21481InvestigationalVevorisertib is under investigation in clinical trial NCT02761694 (Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations
Aceprometazine
go.drugbank.com/drugs/DB01615ExperimentalAceprometazine is a is a drug with neuroleptic and anti-histamine properties. Although not widely prescribed, it is used in combination with meprobamate for the treatment of sleep disorders in France under the trade name Mepronizine.
AIT-034
go.drugbank.com/drugs/DB06106ExperimentalThere is some evidence that AIT-034 could complement Neotrofin as a treatment for Alzheimer's disease and dementia.
Oglufanide
go.drugbank.com/drugs/DB05779InvestigationalOglufanide works as a regulator of the body's immune response, is being given by intranasal administration to patients with chronic hepatitis C viral infection.
Fleroxacin
go.drugbank.com/drugs/DB04576ExperimentalFleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.
POT-4
go.drugbank.com/drugs/DB06056InvestigationalPOT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD). The investigational drug was under investigation in clinical trial NCT00473...
Meropenem
go.drugbank.com/drugs/DB00760ApprovedInvestigationalMeropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall ...
Lefradafiban
go.drugbank.com/drugs/DB04863InvestigationalLefradafiban is an oral platelet glycoprotein IIb/IIIa receptor antagonist being investigated in the treatment of angina.